ZN-A-1041 + capecitabine + trastuzumab

ZN-A-1041 + capecitabine + trastuzumab is a combination therapy under investigation for the treatment of HER2-positive advanced solid tumors, including breast cancer with brain metastases. ZN-A-1041 (also known as Perzebertinib) is an orally bioavailable, selective inhibitor of the human epidermal growth factor receptor 2 (HER2), a receptor tyrosine kinase implicated in tumor cell proliferation and survival. Capecitabine is an oral prodrug of 5-fluorouracil, a cytotoxic antimetabolite that inhibits DNA synthesis. Trastuzumab (Herceptin) is a monoclonal antibody targeting HER2, blocking its signaling and mediating immune responses against tumor cells. Preclinical and early clinical studies have shown that this combination can improve intracranial antitumor activity compared to single agents or other combinations in models of HER2-positive breast cancer with brain metastases[4][6]. The regimen has demonstrated encouraging efficacy and tolerability in phase 1 trials for patients who are TKI-naïve or have progressed on prior therapies[6].

Other names

capecitabinetrastuzumab